.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Lenacapavir provides a transformative twice-yearly injection option for patients with multi-drug resistant HIV. However, its unique metabolic profile demands careful clinical management. Because it acts as a moderate CYP3A4 inhibitor, Lenacapavir drug-drug interactions can significantly alter the levels of co-administered medications. Recent clinical evidence highlights specific concerns regarding corticosteroids and antiplatelet therapies that providers must address. Consequently, vigilance is necessary when integrating this long-acting agent into complex antiretroviral regimens.
In one reported case, a patient receiving lenacapavir used inhaled and nasal fluticasone for respiratory symptoms. Inhibition of the CYP3A4 enzyme by lenacapavir led to systemic accumulation of the steroid. As a result, the patient developed symptoms consistent with adrenal insufficiency and displayed a low baseline cortisol concentration. Fortunately, switching the patient to beclomethasone, which relies less on CYP3A4 metabolism, allowed for clinical improvement. This case underscores why healthcare providers should evaluate alternative steroids or use the lowest possible dose when managing patients on lenacapavir.
Another case involved a patient prescribed clopidogrel following an acute cerebrovascular event. While clinicians eventually discontinued the medication without harm, the interaction remains a point of caution. Specifically, lenacapavir may decrease the conversion of clopidogrel to its active metabolite, potentially reducing its antiplatelet efficacy. Therefore, physicians should carefully monitor therapeutic outcomes or consider alternative agents like prasugrel. Additionally, institutions should update their electronic medical record (EMR) alerts to flag these interactions. Ultimately, proactive monitoring ensures that the benefits of novel long-acting therapies outweigh the risks of drug-related complications.
Lenacapavir inhibits the CYP3A4 enzyme, which is responsible for metabolizing fluticasone. This inhibition can lead to increased systemic levels of the corticosteroid, potentially causing Cushing's syndrome or adrenal insufficiency.
Clinical data suggests that beclomethasone is a safer alternative to fluticasone. It has a lower potential for clinically significant interactions with CYP3A4 inhibitors, making it more suitable for patients receiving lenacapavir injections.
Since lenacapavir is a newer agent, many EMR systems do not yet include comprehensive interaction alerts. Updating these systems to mirror alerts for protease inhibitors can help prevent dangerous drug combinations and improve patient safety.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Pecora Fulco P et al. A precautionary tale of lenacapavir drug-drug interactions: A case series of two persons living with HIV receiving long-acting injections. Int J STD AIDS. 2026 Jun 18. doi: 10.1177/09564624261461789. PMID: 42312466.
NIH. Drug-Drug Interactions: Capsid Inhibitors and Other Drugs. Clinical Info HIV.gov. Updated September 2024.
Marzolini C et al. Drug-drug interactions potential with the HIV-1 capsid inhibitor lenacapavir. Expert Opin Drug Metab Toxicol. 2024 Oct 16. doi: 10.1080/17425255.2024.2415148.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This case series details significant Lenacapavir drug-drug interactions in HIV patients. It highlights the risk of adrenal insufficiency with fluticasone and potential efficacy issues with clopidogrel, emphasizing the need for updated electronic medical record alerts to ensure patient safety.
2 months ago
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
Last week
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
4 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
Last week
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
4 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
Last week
